Publicação
Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes
| Resumo: | Diabetes mellitus is a chronic disease that occurs when one cannot produce or use insulin effectively. Almost 500 million people live with this issue, which means they are more prone to comorbidities such as obesity or overweight. The current worldwide scenario is already being termed an epidemic. In order to overcome the risks associated with these clinical factors, glucagon-like peptide 1 receptors have emerged as a promising intervention as they have demonstrated multifaceted metabolic benefits. Due to the recent introduction of this pharmaceutical in people with type 1 diabetes, many studies are still unfolding to understand its limitations and long-term consequences better. Through a predictive model, this study identifies individual and clinical characteristics that may influence response to treatment. Moreover, given the high price of the drug, the model can serve as a validation tool for medical teams to assess whether the patient will achieve the expected outcome, contributing to the effective management of the substance. The results and validation metrics indicate that the predictive model successfully predicted the response to treatment and identified the factors that contributed to the success of the treatment, highlighting that the early stages of overweight are the optimal time to start the therapy. Additionally, it was found that patients with an optimised glycaemic control (low glycosylated haemoglobin levels) have less treatment efficacy. This study is especially valuable for healthcare professionals, leading to personalised treatment strategies and supporting treatment decision-making. Furthermore, it is an innovative study in terms of content since no literature combines these agonists for type 1 diabetes with a predictive perspective. |
|---|---|
| Autores principais: | Cordeiro, Alexandra do Céu Gonçalves |
| Assunto: | Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| Ano: | 2024 |
| País: | Portugal |
| Tipo de documento: | dissertação de mestrado |
| Tipo de acesso: | acesso embargado |
| Instituição associada: | Universidade Nova de Lisboa |
| Idioma: | inglês |
| Origem: | Repositório Institucional da UNL |
| _version_ | 1868983570822856704 |
|---|---|
| author | Cordeiro, Alexandra do Céu Gonçalves |
| author_facet | Cordeiro, Alexandra do Céu Gonçalves |
| author_role | author |
| contributor_name_str_mv | António, Nuno Miguel da Conceição RUN |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Cordeiro, Alexandra do Céu Gonçalves\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | António, Nuno Miguel da Conceição RUN |
| datacite.creators.creator.creatorName.fl_str_mv | Cordeiro, Alexandra do Céu Gonçalves |
| datacite.date.Accepted.fl_str_mv | 2024-10-31T00:00:00Z |
| datacite.date.available.fl_str_mv | 2026-10-31T00:00:00Z |
| datacite.date.embargoed.fl_str_mv | 2026-10-31T00:00:00Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_f1cf |
| datacite.subjects.subject.fl_str_mv | Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| datacite.titles.title.fl_str_mv | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| dc.contributor.none.fl_str_mv | António, Nuno Miguel da Conceição RUN |
| dc.creator.none.fl_str_mv | Cordeiro, Alexandra do Céu Gonçalves |
| dc.date.Accepted.fl_str_mv | 2024-10-31T00:00:00Z |
| dc.date.available.fl_str_mv | 2026-10-31T00:00:00Z |
| dc.date.embargoed.fl_str_mv | 2026-10-31T00:00:00Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10362/175135 |
| dc.language.none.fl_str_mv | eng |
| dc.rights.cclincense.fl_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_f1cf |
| dc.subject.none.fl_str_mv | Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| dc.title.fl_str_mv | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_bdcc |
| description | Diabetes mellitus is a chronic disease that occurs when one cannot produce or use insulin effectively. Almost 500 million people live with this issue, which means they are more prone to comorbidities such as obesity or overweight. The current worldwide scenario is already being termed an epidemic. In order to overcome the risks associated with these clinical factors, glucagon-like peptide 1 receptors have emerged as a promising intervention as they have demonstrated multifaceted metabolic benefits. Due to the recent introduction of this pharmaceutical in people with type 1 diabetes, many studies are still unfolding to understand its limitations and long-term consequences better. Through a predictive model, this study identifies individual and clinical characteristics that may influence response to treatment. Moreover, given the high price of the drug, the model can serve as a validation tool for medical teams to assess whether the patient will achieve the expected outcome, contributing to the effective management of the substance. The results and validation metrics indicate that the predictive model successfully predicted the response to treatment and identified the factors that contributed to the success of the treatment, highlighting that the early stages of overweight are the optimal time to start the therapy. Additionally, it was found that patients with an optimised glycaemic control (low glycosylated haemoglobin levels) have less treatment efficacy. This study is especially valuable for healthcare professionals, leading to personalised treatment strategies and supporting treatment decision-making. Furthermore, it is an innovative study in terms of content since no literature combines these agonists for type 1 diabetes with a predictive perspective. |
| dirty | 0 |
| eu_rights_str_mv | embargoedAccess |
| format | masterThesis |
| fulltext.url.fl_str_mv | https://run.unl.pt/bitstreams/b2c5a508-c974-4c44-8f30-0f8d4e8b0b2c/download |
| id | run_633c19d1b47005d1d6e6f0ed4ac8fdc2 |
| identifier.url.fl_str_mv | http://hdl.handle.net/10362/175135 |
| inst_facet_str | urn:organizationAcronym:unl{{{_:::_}}}Universidade Nova de Lisboa |
| instacron_str | unl |
| institution | Universidade Nova de Lisboa |
| instname_str | Universidade Nova de Lisboa |
| language | eng |
| network_acronym_str | run |
| network_name_str | Repositório Institucional da UNL |
| oai_identifier_str | oai:run.unl.pt:10362/175135 |
| organization_str_mv | urn:organizationAcronym:unl |
| person_str_mv | Cordeiro, Alexandra do Céu Gonçalves |
| publishDate | 2024 |
| repo_facet_str | urn:repositoryAcronym:run{{{_:::_}}}Repositório Institucional da UNL |
| reponame_str | Repositório Institucional da UNL |
| repository_id_str | urn:repositoryAcronym:run |
| service_str_mv | urn:repositoryAcronym:run |
| spelling | engpt_PTDiabetes mellitus is a chronic disease that occurs when one cannot produce or use insulin effectively. Almost 500 million people live with this issue, which means they are more prone to comorbidities such as obesity or overweight. The current worldwide scenario is already being termed an epidemic. In order to overcome the risks associated with these clinical factors, glucagon-like peptide 1 receptors have emerged as a promising intervention as they have demonstrated multifaceted metabolic benefits. Due to the recent introduction of this pharmaceutical in people with type 1 diabetes, many studies are still unfolding to understand its limitations and long-term consequences better. Through a predictive model, this study identifies individual and clinical characteristics that may influence response to treatment. Moreover, given the high price of the drug, the model can serve as a validation tool for medical teams to assess whether the patient will achieve the expected outcome, contributing to the effective management of the substance. The results and validation metrics indicate that the predictive model successfully predicted the response to treatment and identified the factors that contributed to the success of the treatment, highlighting that the early stages of overweight are the optimal time to start the therapy. Additionally, it was found that patients with an optimised glycaemic control (low glycosylated haemoglobin levels) have less treatment efficacy. This study is especially valuable for healthcare professionals, leading to personalised treatment strategies and supporting treatment decision-making. Furthermore, it is an innovative study in terms of content since no literature combines these agonists for type 1 diabetes with a predictive perspective.application/pdfpt_PTAssessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 DiabetesCordeiro, Alexandra do Céu GonçalvesAntónio, Nuno Miguel da ConceiçãoHostingInstitutionOrganizationalRUNe-mailmailto:run@unl.ptrun@unl.ptURNurn:tid:2037773792024-10-312026-10-31T00:00:00Z2024-10-31T00:00:00ZHandlehttp://hdl.handle.net/10362/175135http://purl.org/coar/access_right/c_f1cfembargoed accessDiabetesObesityGlucagon-Like Peptide 1 Receptor AgonistsPredictive ModelSDG 3 - Good health and well-being1348928 bytesliteraturehttp://purl.org/coar/resource_type/c_bdccmaster thesis2024-10-31http://creativecommons.org/licenses/by/4.0/http://purl.org/coar/access_right/c_f1cfapplication/pdffulltexthttps://run.unl.pt/bitstreams/b2c5a508-c974-4c44-8f30-0f8d4e8b0b2c/download |
| spellingShingle | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes Cordeiro, Alexandra do Céu Gonçalves Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| status | SINGLETON |
| subject.fl_str_mv | Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| title | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| title_full | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| title_fullStr | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| title_full_unstemmed | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| title_short | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| title_sort | Assessing the Therapeutic Efficacy of GLP-1 Receptor Analogues in Overweight or Obese Individuals with Type 1 Diabetes |
| topic | Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| topic_facet | Diabetes Obesity Glucagon-Like Peptide 1 Receptor Agonists Predictive Model SDG 3 - Good health and well-being |
| url | http://hdl.handle.net/10362/175135 |
| visible | 1 |